Victor Rivera - 01 Mar 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Role
Chief Scientific Officer
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 06:02:49 UTC
Previous filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Restricted Stock Units Award $0 +16,250 $0.000000 16,250 01 Mar 2023 Common Stock 16,250 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2 The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date.